Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

The 2014 ASCO Gastrointestinal (GI) Cancer Symposium takes place in San Francisco from Jan 16-18 and is the second meeting in this year’s oncology conference calendar. GI cancers include oesophageal, gastric, colorectal and pancreatic cancers, as well as hepatocarcinoma or HCC (liver).

You can follow any tweets from ASCO GI using the hashtag #GI14.

This year, the topics that most caught my eye in the program were pancreatic and gastric cancers.

This post provides insights on the key studies that looked interesting to me at this event, based on the schedule available.  The abstracts will be available on January 14th and can be accessed here.

Companies mentioned: Celgene, Lilly, Roche/Genentech, Aduro Biotech
Drugs mentioned:  Abraxane, Gemzar, ramucirumab, Avastin, Herceptin, GVAX

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

Posted by 

2 Responses to “ASCO GI 2014 Preview: Pancreatic and Gastric Cancer”

  1. Miguel

    Hi Sally, do you expect more mature data on pegph20 plus gemcitabine? Do you have an opinion on pegph20 and specifically on its MOA? Thanks

    • maverickny

      Hi Miguel, I couldn’t find anything in the program on PEGPH20 in either the poster or oral abstracts, which suggests there may not be any new data yet. However, I am reliably informed that one of the key PIs will be at the meeting, will see if I can track him down.

      As for the data so far, the I thought the preclinical data was interesting but in reality, the subsequent phase I data was rather meh, I’m afraid. It’s a nice idea – kind of like the blasting through the stromal layer with Abraxane concept, but hit HA instead. We will have to wait for the phase II data to see what happens and whether the responses are correlated with stromal HA levels or not.

Comments are closed.

error: Content is protected !!